CANBRIDGE PHARM.DL-00001 (MF1) — Net Asset Momentum
CANBRIDGE PHARM.DL-00001 (MF1) recorded a net asset momentum of 28.0% as of December 2025, with net assets of €-341.75 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See CANBRIDGE PHARM.DL-00001 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
CANBRIDGE PHARM.DL-00001 Net Asset Momentum (2021–2025)
This chart tracks CANBRIDGE PHARM.DL-00001's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +28.0%, with net assets of €-341.75 Million EUR as of December 2025. Read MF1 liabilities breakdown for a breakdown of total debt and financial obligations.
Annual Net Asset History for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the complete annual net asset history for CANBRIDGE PHARM.DL-00001 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see MF1 company net worth.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-341.75 Million | €165.39 Million | €507.15 Million | ▲ +28.0% |
| 2024 | €-474.49 Million | €116.81 Million | €591.30 Million | ▼ -1092.5% |
| 2023 | €-39.79 Million | €395.36 Million | €435.15 Million | ▼ -112.9% |
| 2022 | €308.56 Million | €702.04 Million | €393.49 Million | ▼ -55.5% |
| 2021 | €693.39 Million | €892.52 Million | €199.13 Million | — |